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Objectives: To systematically review studies of antiemetics used in the treatment of 
nausea in patients with far-advanced cancer. 
Data Sources: Randomized controlled trials (RCT) and uncontrolled studies 
identified by electronic and hand searching. 
Review methods: Identified studies were appraised for quality and effect size. 
Results: Twenty-one studies were included. Two were systematic reviews, seven 
were randomised controlled trials (RCT) and 12 were uncontrolled studies or case 
series. Differences in interventions and outcomes amongst the RCT precluded any 
quantitative data synthesis and all seven studies were prone to bias. Whereas 
uncontrolled studies indicated a high response rate to standard regimens (75-93% for 
both nausea and vomiting), RCT produced much lower response rates to these agents 
(23-36% for nausea, 18-52% for vomiting). The two methods of antiemetic choice 
(choice based on either the inferred mechanism or else empiric) were equally 
effective. There is reasonably strong evidence for the use of metoclopramide in 
cancer-associated dyspepsia and steroids in malignant bowel obstruction. There was 
conflicting evidence about the efficacy of serotonin antagonists compared with 
standard treatments (e.g. metoclopramide, dopamine antagonists or dexamethasone). 
There is little or no evidence about the efficacy of some commonly used and 
seemingly effective drugs such as haloperidol, cyclizine, or methotrimeprazine.  
Conclusion: Evidence supporting the existing consensus-based guidelines for 
management of nausea and vomiting in advanced cancer is sparse.  Current 
approaches to treatment based on the neuropharmacology of the emetic pathway may 
be inappropriate in this setting. Well-designed studies of the impact of “standard” 
management and novel agents on nausea and vomiting in palliative populations are 
needed.    
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Nausea and vomiting are common experiences of patients with advanced cancer, 
independent of exposure to chemotherapy. Approximately 60% of patients with 
advanced cancer report nausea and 30% report vomiting,[Davis] often rating them as 
a source of great distress.[Portenoy] The management of nausea and vomiting is 
prominent in palliative care textbooks [Mannix] but these symptoms are under-treated 
in patients with advanced cancer [Reuben]. The development, dissemination and 
implementation of evidence-based clinical practice guidelines (CPG) based on 
specialist palliative care practice may empower health care professionals to improve 
the management of nausea and vomiting in patients with advanced cancer.  
  
A key feature of specialist palliative care is that the assessment and treatment of 
symptoms is based on a sophisticated understanding of symptom pathophysiology. 
The pathophysiological mechanism is inferred from careful assessment of the 
patient’s history, physical examination and diagnostic test results. This approach is 
best studied for pain,[Ashby] but may provide a useful paradigm for the assessment 
and management of other symptoms. The differential diagnosis of nausea and 
vomiting in patients with advanced cancer is long. Antiemetic choice is based on 
identifying the likely mechanism of the symptoms from the clinical picture and 
applying knowledge of the neuropharmacology of the emetic pathway [Grunberg, 
Peroutka]. Experts in the field claim that the cause of nausea and vomiting can be 
determined clinically in 90% cases [Bentley, Lichter1], although they recognise that 
the cause is usually multifactorial. It is claimed that more than 80% of patients can 
have their nausea and vomiting controlled when treated in this way [Bently, lichter2]. 
The evidence upon which this claim is made warrants review. 
 
Based on the success of educational interventions for assessing and treating cancer 
pain, we propose to develop an evidence-based CPG for non-specialist clinical 
providers of palliative care to guide their assessment and treatment nausea in patients 
with advanced cancer. The purpose of this systematic review (SR) was to evaluate all 
known controlled and non-controlled trials pertaining to the efficacy of 
pharmacological therapy for nausea in advanced cancer, in order to inform the 
development of the CPG. It was expected that the number of studies identified would 




The review conformed to the QUOROM statement’s standards for improving the 
quality of reports of meta-analyses [Moher] and the criteria for informing CPG 
development outlined by the National Health and Medical Research Council 
(NHMRC) of Australia [NHMRC]. The assessment of study quality was based on the 
level of evidence provided, validity of the results and the effect sizes reported. 
 
2.1 Search strategy 
The search was carried out in three steps. The search strategy for the identification of 
studies included (a) electronic searching of the US Clinical Guidelines Repository 
[www.guideline.gov] and the Cochrane Library’s Systematic Review And Clinical 
Trial Registry, (b) the Ovid Medline and EmBase electronic databases of the medical 
literature, and (c) hand-searching of targeted sources.  
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The search of the Clinical Guidelines Repository and the Cochrane Library used the 
search terms nausea, cancer and palliative care. The Ovid Medline (1966-week 4, 
June 2003) search used combinations of the key words and exploded Medical Subject 
Headings (MeSH) terms nausea, vomiting, antiemetics, palliative care, hospices, 
hospice care, terminal care, and neoplasms. The initial search was limited to studies 
in humans published in English. The identified citations were then further limited to 
meta-analyses, randomised-controlled trials and clinical studies. The same terms were 
used for the EmBase (1980 - 2003 week 26) search. 
 
To identify any articles missed by the electronic search, the bibliographies of the 
electronically identified articles and consensus-based guidelines, and the chapter on 
nausea and vomiting of the Oxford textbook of Palliative Medicine (2nd edition) 
[Mannix] were hand-searched. The Table of Contents of all issues of five palliative 
care journals that publish experimental data (Palliative Medicine, Journal of Pain and 
Symptom Management, Journal of Palliative Care, Journal of Palliative Medicine, 
Supportive Care in Cancer) and three major oncology journals from 1993 to mid-2003 
(Journal of Clinical Oncology, Cancer, British Journal of Cancer; all 1993-present) 
were also hand-searched.  
 
  
2.2 Study characteristics and selection 
Publications from the various sources were screened for retrieval according to their 
titles. Systematic reviews, randomised controlled studies, Phase I/II clinical trials, 
well-designed cohort/case-control studies and case series were considered. Single 
case-reports, clinical examples and expert opinions were excluded. If the title of the 
study appeared relevant, the abstract was read and screened for the following pre-
determined inclusion/exclusion criteria: 
(i) the study involved clinical research in humans 
(ii) the study participants had cancer at an advanced stage  
(iii) the study objective was to evaluate a pharmacological intervention aimed at 
controlling emesis and the intervention was clearly described 
(iv) the study objective was not primarily aimed at evaluating (a) antiemetics for 
the control of nausea and vomiting caused by emetogenic chemotherapy (b) 
agents for the treatment of bowel obstruction other than the standard 
antiemetics (such as surgery, tubes, or drugs intended to control secretions 
such as hyoscine or octreotide), and  
(v) the Results section reported a clearly-described measurement of the baseline 
symptoms and the treatment effect (reduction of nausea or vomiting, measured 
either subjectively or objectively). 
The full article was retrieved for more detailed evaluation only if it met all of these 
criteria and was published in English. 
 
2.3 Validity assessment 
The level of evidence was determined using the NHMRC criteria (Table 1). The risk 
of bias in the randomised trials and the quasi-experimental studies was evaluated 
independently by two of the authors (PG, GP) according to the Methods for 
Evaluating Research Guideline Evidence (MERGE) document (Table 2).[Liddle] The 
results were then compared and disagreements resolved by consensus. The major 
source of bias to be identified in the case of the SR was publication bias. The major 
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sources of bias to be identified in primary trials included non-concealment of 
treatment allocation (in the case of randomised trials) and loss to follow up and failure 
to carry out an intention-to-treat analysis (in both randomised and non-randomised 
trials).  
   
2.4 Data abstraction and quantitative data synthesis 
The first author abstracted the data. It was anticipated that the quality of the studies 
and the nature of the data would preclude quantitative data synthesis. If quantitative 
data synthesis appeared possible, it was planned to consult a biostatistician to assess 
the data for heterogeneity, to combine the results and to quantify the extent of any  
publication bias; no a priori sensitivity or subgroup analyses were under consideration 
prior to the commencement of the review. 
 
3. RESULTS 
3.1 Trial flow. 
The search of the web-based Clinical Guideline Repository yielded 50 citations, of 
which three concerned nausea and one of which appeared relevant [Finnish]. 
However, this guideline was not evidence based, contained no data and provided no 
references and was therefore excluded. The search of the Cochrane Library resulted in 
48 citations regarding nausea and vomiting in cancer, however none was deemed 
relevant to the topic of this review. A Cochrane review of steroids for the relief of 
bowel obstruction was missed by the search but was subsequently identified as a 
Topic Review while performing the Medline search.  
 
The initial Medline and EmBase searches for nausea and vomiting in advanced cancer 
produced a list of more than 1100 citations, of which only 22 (1.9%) had titles that 
appeared relevant to the topic of the review. Limiting the search to meta-analyses 
revealed seven citations, only one of which appeared relevant [44], the others all 
relating to chemotherapy-induced emesis. A systematic review of haloperidol, 
published as a letter and not coded electronically as a systematic review, was found 
subsequently when searching for uncontrolled studies [Critchley].  
 
Limiting the electronic search to RCT resulted in the identification of five relevant 
publications out of almost 400 citations that were retrieved for closer 
evaluation.[Hardy 02, Bruera 94, Bruera 00, Mystakidou, Mystakidou]. Seven 
uncontrolled studies were also located electronically that met the review criteria 
[Bentley, Wilson, bruera, lichter, Jackson. Currow], .  
 
Hand searching revealed one randomized trial [Corli] and two uncontrolled studies 
[Porcel, TwyX] that had been missed by the electronic search. No meta-analyses or 
SR were missed. Three guidelines or algorithms were also identified that were not 
included in the online repository.[TGA, Regnard, Twyx&Back]. None was evidence-
based.  
 
A second electronic search for studies specifically about nausea in inoperable bowel 
obstruction revealed 77 publications of which 12 (16%) appeared relevant. Five of the 
twelve met the inclusion criteria consisting of one meta-analysis,[Feuer] the two RCT 
considered in the meta-analysis [Hardy 98, laval] and two case series.[baines, 




3.2 Study characteristics 
Twenty-two studies were initially assessed (see Tables 2 and 3). There were nine 
studies providing NHMRC Level I or II evidence and 11 studies providing Level III 
or IV evidence (uncontrolled studies or cases series). The Level I/II studies consisted 
of two SR [Critchley, Feuer] and eight RCT, six on nausea [Hardy 02, bruera 94,00; 
Corli, mystakX2] and two on bowel obstruction [hardy 98, laval]. One RCT on nausea 
that met the inclusion criteria was excluded after retrieval when it was found to 
contain duplicate data published in another included study [Mystak]. The 
electronically identified “meta-analysis” turned out to be an uncontrolled study 
[Wilson]. Ultimately, 21 studies were included in the review: two systematic reviews, 
seven RCT and 12 uncontrolled studies.  
 
3.3 Quality appraisal 
The quality of the Level I-III studies was appraised. The SR were at low risk of 
publication bias but the evidence they provide on the control of nausea is weak. The 
results of the quality appraisal of the Level II-III studies are shown in Table 2. The 
majority of the primary RCT were at low-moderate risk of bias. Strengths of the RCTs 
included: blinding, use of valid and objective measures and use of intention to treat 
analysis. The main weaknesses of  the studies were failure to state how the allocation 
of randomisation was concealed, loss to follow-up, and failure to undertake studies at 
more than one centre so that reproducibility of the results is unknown. The two 
assessors agreed on 40/56 (71%) ratings of methodologic quality for the seven RCT; 
the differences were resolved by consensus.  
 
The Level III studies were even more susceptible to bias: all were rated as being of at 
least moderate-to-high risk of bias. The main strengths of the Level III studies were 
that refusals were well documented, and there was complete follow-up. The main 
weaknesses were that the populations were poorly defined, the measures were not 
validated, there was no adjustment for confounders, and they were all single centre 
studies. 
  
All but one of the RCT were small (<100 patients) and few had the sample size based 
on a power calculation. Measurement of effect was generally simplistic (e.g. 
percentage of responses to treatment). Confidence intervals or other indicators of the 
precision of these estimates of effect size were not given in any of the studies.  
  
3.4 Quantitative data synthesis 
The five RCT on nausea compared very different populations, treatment regimens and 
outcome measures, so a quantitative data synthesis was impossible. Qualitative 
syntheses of the study results are summarised in Table 3 and 4. Whereas the 
uncontrolled studies had high response rates (75-93%) to standard regimens, the 
RCTs had much lower responses rates (23-36% for nausea, 18-52% for vomiting). 
Similar response rates were achieved whether drug selection was empiric [Bruera, 
Bruera, Corli, Mystakidou] or based on the patient’s clinical picture.[Hardy, Bentley, 
lcihter, Wislon]  
 
Metoclopramide was superior to placebo in one of two small, controlled 
studies.[Hardy 02, bruera 00] The evidence for many other anti-emetics that are used 
routinely in palliative care, such as haloperidol, prochlorperazine, cyclizine and 
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methotrimeprazine is weak or non-existent [Cirtchley, Lichter, Bentley, Twycross]. 
This is also the case for newer agents like olanzepine and  synthetic cannabis 
derivatives [Jackson, passik, Walsh).  
 
One RCT of the dopamine-antagonist levosulpride found it to be superior to 
metoclopramide [Corli]. A small body of experimental data suggests serotonin 
antagonists may be at least as effective in the management of nausea in advanced 
cancer - if not more so - as the traditionally used antiemetics such as metoclopramide, 
dopamine antagonists and dexamethasone.[Currow, hardy, Mystak, porcel].  
 
In the case of bowel obstruction, steroids appear to be effective in hastening its 
resolution but there is no data as to whether they are anti-emetic per se {Feuer, Hardy 
98, Laval] While there is Level I evidence for the use of steroids in bowel obstruction, 
the effect size obtained was small and showed a non-significant statistical trend for 





This review has shown that the evidence base for the pharmacological treatment of 
nausea and vomiting in advanced cancer practiced by palliative care specialists is 
generally weak and contradictory. The small number of well-designed studies, the 
variation in the interventions studied and the lack of uniformity in outcome 
measurement precluded a formal meta-analysis of the results of the review being 
performed. Not surprisingly, the response rates to anti-emetic treatment were lower in 
the controlled studies than the uncontrolled ones. The findings of this review have 
major implications for clinicians and researchers.  
 
There are two possible approaches to drug selection for controlling symptoms such as 
nausea.  The  “mechanistic” approach, favoured by palliative care specialists, attempts 
to infer the pathophysiological abnormality producing nausea from the patient’s 
clinical picture and anti-emetic selection is based on the current understanding of the 
neuropharmacology of the emetic pathway [Lichter1]. Alternatively, an empiric 
approach can be followed, trialing various anti-emetics without regard to the 
underlying cause of the nausea. The two prospective audits of current practice 
[Bentley, lichter2] suggest the mechanistic approach is effective. The empiric 
approach may also be highly effective [Bruera, bruera, Mystak, Corli] however and 
the two have not been directly compared. If a mechanistic approach is to be followed, 
it is unclear whether an accompanying algorithm for prescribing is needed [bentley] 
or not [Lichter2]; either way, 80-90% of nausea responds to treatment. Empiric use of 
anti-emetics acting on multiple receptors, such as methotrimeprazine, olanzepine and 
levosulpride may be as effective as more specific agents selected by the mechanistic 
approach, but research on this possibility is needed.  
 
Support for adhering to a mechanistic approach to drug selection is provided by the 
studies of metoclopramide, which has been the most widely studied agent. 
Metoclopramide appears to be more effective than placebo,[Bruera 00, hardy] with a 
75% response rate when used for a gastroparetic mechanism (the cancer-associated 
dyspepsia syndrome,[Bruera00]) compared to a 30% response rate when prescribed  
empirically [Bruera 96, Mystak]. There is very little evidence from well-designed 
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studies for other anti-emetic agents that are widely prescribed in palliative care such 
as haloperidol, cyclizine and methotrimeprazine While a systematic review of 
haloperidol has been published [Critchley], the current evidence base is weak. Well-
designed studies testing the efficacy of these agents are urgently needed. 
 
The efficacy of steroids as antiemetics is also dependent on the approach to drug 
selection that is taken. Used empirically, steroids have been used as adjuvants in 
patients with nausea not responding to other therapy, although the results are 
conflicting [Bruera, mystak]. Taking a mechanistic approach, there is Level I 
evidence for the effectiveness of steroids in symptomatic malignant bowel 
obstruction. This conclusion is based on just two controlled studies involving a total 
of only 89 patients [Feuer] and the effect size was small (NNT 6, 95% CI 3 to ∞). 
Studies of scopolamine and octreotide in malignant bowel obstruction were 
intentionally excluded from the review because of the scope of the proposed CPG 
(Ripamonti, mercadente).  
 
The previously limited use of 5HT3 receptor antagonists in palliative care practice 
may need to be reviewed given that there have now been two RCT supporting the 
findings of previous positive case series and case reports. Although one of the studies 
found only a non-significant trend favouring ondansetron over placebo, it may have 
been statistically under-powered to detect a difference [Hardy 02]. In the other study, 
tropisetron was more effective than conventional agents like metoclopramide and 
chlorpromazine but drug selection was empiric and deficiencies in the study design, as 
reported, meant the results were at a high risk of bias [Mystak]. Because the chronic 
nausea associated with advanced cancer is multifactorial and involves many different 
receptor systems, the large body of evidence for the treatment of acute nausea and 
vomiting due to highly emetogenic chemotherapy has not been considered [Bartlett]. 
Because of concerns over toxicity, such as constipation, and the cost of therapy, more 
well designed studies of the 5HT3 receptor antagonists for the nausea associated with 
far-advanced cancer are needed. 
  
While there remains such a paucity of data from well-designed and clearly described 
studies, the management of nausea in advanced cancer will continue to be based on 
expert opinion rather than evidence. Inference from the basic science of the emetic 
pathway will also continue, even though it may not be the appropriate paradigm. At 
least most of the standard antiemetics are inexpensive and well tolerated. More 
research is needed before expensive agents like the serotonin antagonists and 
olanzepine can be recommended.  
 
As with many areas of palliative care, the lack of evidence for current practice is due 
to an absence of data rather than a body of negative results. The implication of this 
review is not to cease current practice in treating nausea in patients with advanced 
cancer. Rather, it highlights that well-designed, high-quality studies to test and refine 
the hypotheses raised by more than thirty years of clinical experience are urgently 
needed. Only then will it become clear how relevant are our current approaches and 
how we can best use currently available treatments. 
 
Based on the results of this review, the following nine recommendations, graded with 
supporting evidence, as the basis for CPG, using the grades of recommendations 
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proposed by the US Department of Health and Human Services’ Agency for Health 
Care Policy and Research:[AHCPR]  
 
• the current mechanistic approach to the management of nausea in advanced cancer 
which is based on the neuropharmacology of the putative “emetic pathway”  
should be the basis for choosing first-line antiemetic drugs (grade of 
recommendation: B; references: Bentley, lichter)  
• utilizing a CPG may effective for the management of nausea and vomiting in 
patients with advanced cancer (C; Finland, regnard, Twy&Back, TGL)  
• metoclopramide is effective in the management of nausea in advanced cancer 
(A;Bruerax3, hardy) 
• haloperidol may be effective in the management of nausea in advanced cancer (C; 
Bentley, lichter, Vf, Critchley) 
• other standard antiemetics recommended for the  management of nausea in 
advanced cancer, including cyclizine, steroids and methotrimeprazine may be 
effective in the management of nausea in advanced cancer (B; Lichter, Bentley, 
Twyx) 
• serotonin antagonists are more effective than metoclopramide and chlorpromazine 
in the management of nausea and vomiting from advanced cancer (A; hardy, 
mystak) 
• the novel agent olanzepine may be effective in the management of nausea in 
advanced cancer (B; Passik, Jackson) 
• cannabinoids like nabilone may be effective in the management of nausea in 
advanced cancer (C; Walsh) 
• steroids are effective in hastening the resolution of bowel obstruction (A; Feuer) 
 
Grade of recommendations: 
A: at least one RCT as part of a body of literature of good quality and 
consistency addressing the specific recommendation 
B: well conducted clinical studies but no RCT on the topic of the 
recommendation 
C: evidence from expert committee reports or opinions, or opinions of 
respected clinical authorities; no directly applicable clinical evidence of good 
quality 
 
Like any SR, this summary of evidence is prone to publication bias. Although the two 
main medical electronic databases (Medline, EmBase) were accessed, other databases 
(e.g. Cancer Lit, CINAHL, Current Contents) could also have been searched. Ideally, 
the searches would have been re-run using the MeSH terms of the studies that were 
identified by the hand-search. However, only two such articles were found,[9,13]  the 
sensitivity of the search was good, and its specificity was extremely low. Other data 
sources could have been pursued including searching for unpublished studies through 
conference abstracts, theses and contacting authors. Such an exhaustive approach was 
beyond the available resources.  
 
The extensive hand searching undertaken was a strength of this study, given the 
relatively high rate of published palliative care articles that do not appear on 
electronic databases. Only one investigator carried out the publication retrieval, which 
is a potential methodological weakness. However, in view of the low specificity of the 
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search strategy it was not feasible for more than one person to retrieve the 
publications within the available resources.  
    
It is clear that much more research needs to be done on the pharmacological 
management of nausea in patients with advanced cancer. Well-designed studies using 
standard regimens and agreed outcomes of all agents – standard and novel – are 
needed. Placebo-controlled studies may be justified but are unlikely to be acceptable 
in clinical practice and to institutional review boards. It is particularly important to 
compare newer, more expensive drugs (eg serotonin antagonists, olanzepine, 
aprepitant [Chawka] ) with conventional, cheaper drugs (eg metoclopramide, 
haloperidol, cyclizine). 
 
More research is needed on the epidemiology and assessment of nausea and vomiting. 
There are few studies on the incidence, prevalence or frequency of nausea and 
vomiting. There are currently no well-established assessment tools. The results of this 
study also reinforce the need, recognised by others,[Bruera 87] to rethink our 
approach to the management of nausea in advanced cancer which is currently based 
on the mono-mechanistic paradigm of chemotherapy induced emesis. While this may 
be appropriate in some circumstances, e.g. opioid-induced emesis, in many cases, the 
cause of nausea in advanced cancer is multifactorial and multidimensional and 
involves systems other than the “emetic pathway” that determines chemotherapy-
induced emesis. Even if the neuropharmacology of the emetic pathway is appropriate 
for advanced cancer, the previous insistence on using single agents to affect specific 
receptors may be passe, as many of these agents are known to affect multiple 
receptors [Peroutka, twycross]. Clinical trials of “dirty” drugs like methotrimeprazine 
are needed.  
 
If drugs like the serotonin antagonists become more important in palliative care, then 
the emerging field of pharmacogenomics will also become more relevant to palliative 
care [Mcleod]. These and many other drugs commonly used in palliative care (e.g. 
codeine, dexamethasone, NSAID) are metabolized by, induce or inhibit enzymes in 
the Cytochrome P450 system [Rogers] and the effect of genetic polymorphism on this 
system are also being recognized [Bernard]. A pharmacodynamic interaction between 




Evidence supporting the existing consensus-based guidelines for management of 
nausea and vomiting in advanced cancer is sparse.  Current approaches to treatment 
based on the neuropharmacology of the emetic pathway may be inappropriate in many 
cases of nausea in this setting. Well-designed studies of the impact of standard 
management and novel agents on nausea and vomiting in palliative populations are  
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Table 1. Designation of levels of evidence (adapted from reference 31). 
 
Level of evidence Study design 
I Systematic review of all relevant RCT 
II At least one properly-designed RCT 
III-1 Well designed pseudo-randomised trials 
III-2 Non-randomised comparative studies, cohort studies, case-
control studies, interrupted time series with a control group 
III-3  Comparative studies with historical control, two or more single 
arm studies, interrupted time series without a control group 
IV Case series, either post test or pre-test/post test 
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Table 2. Quality assessment of the Level II and level III studies, using MERGE 
criteria to evaluate various aspects of study design (columns 2-9) and overall quality 












































Bruera 2000, [8] ? A B A A B A ? BB 
Mystakidou 1998 [29] ? ? B A B B A ? CC 
Corli 1995 [9] D B A A A A A ? BB 
Bruera 1994 [6]  ? A A A A B A ? BB 
 
2. BO 
         
Laval 2000 [22] ? B D ? C C A D CC 
Hardy 1998 [18] ? A A A A B A D BB 
          
 

























1. N&V         
Bentley 
2001 [4] 
B A B N/A B A ? BB 
Wilson 
2002 [44] 
B ? B B C A ? DD 
Bruera 
1996 [7] 
B A B D A N/A ? CC 
Lichter 
1993 [24] 
C A D D A N/A ? CC 
         
2. BO         
Baines 
1985 [2] 




N&V: nausea and vomiting 
BO: bowel obstruction 
CRA:  concealment of randomization allocation 
 
Evaluation criteria 
A: criterion entirely fulfilled 
B: criterion mostly fulfilled 
C: criterion mostly not fulfilled 
D criterion not fulfilled 
?: not described adequately to classify 
n/a: criterion not applicable to this study design 
 
Overall assessment of quality 
AA: all or most criteria fulfilled 
BB: some criteria not fulfilled 
CC: some criteria fulfilled 
DD: few or no criteria fulfilled 
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Table 3. Summary of results of studies providing Level I or II evidence 
 
Table 3A. – Level I studies (systematic reviews)  
Author, year Ref. 
No. 




a. N&V      
Critchley, 2001 10 Haloperidol 3 Low Uncertain (very 
few good quality 
data available) 
      
b. BO      
Feuer, 2003 14 Steroids 3 Low Resolution of BO;  
no data for nausea 
 




Agent(s) N Effect 
a. N&V     
Hardy, 2002 19 Ondansetron  vs. 
metoclopramide vs. 
placebo 




29 Metoclopramide vs. 
Chlorpromazine vs. 
Tropisetron  
288 Tropisetron superior to  
metoclopramide and 
chlorpromazine 
Bruera, 2000   8 Metoclopramide vs. 
Placebo 
26 Metoclopramide superior 
to placebo 
Bruera, 1994   6 CR metoclopramide vs. 
IR metoclopramide 
34 CR formulation at least as 
effective as IR 
Corli, 1998   9 Levosulpride vs. 
Metoclopramide 
30 Levosulpride superior 
     
b. BO     
Hardy, 1998 18 Steroids + cyclizine/ 
haloperidol vs. placebo 
35 Steroids superior 
Laval, 2002 22 Steroids vs. placebo 52 Steroids superior  
 
Legend:  
CR = controlled release 
IR = immediate release 
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Table 4: Summary of results of studies providing Level III or IV evidence.  
 






Agent(s) Study design N Effect 
a. N&V      
Passik, 
2002 




44 Metoclopramide Phase II 48 66%* 
Bentley, 
2001 
  4 Various Cohort 40 82% * 
Bruera, 
1996 




100 75% * 
Lichter, 
1993 
24 Various Cohort 100 93%*  
      
b. BO      
Baines, 
1985 
2 Various Cohort 40 90% 
 
 
Table 4B. – Summary of level IV studies  
 
Author, year Ref. 
No. 
Agent(s) N Effect 
a. N&V     
Jackson, 2003 21 Olanzepine 6 100%* 
Porcel, 1998 33a Ondansetron 10 90%* 
Currow, 1997 11 Ondansetron 16# 81% * 
Twycross, 1997 40 Methotrimeprazine 29 83% * 
     
b. BO     
Ventafridda, 1990 43 Haloperidol 15 80%* 





Legend for Tables 4a and 4b: 
 
* = percentage of patients responding to treatment 
 
n/a = not applicable 
 
 
